Back to Journals » OncoTargets and Therapy » Volume 15

Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report

Total article views   HTML views PDF downloads Totals
7,993 Dovepress* 7,094+ 373 7,467
PubMed Central* 899 180 1,079
Totals 7,993 553 8,546
*Since 2 April 2022

View citations on PubMed Central and Google Scholar